NNNN Stock Forecast: Anbio Biotechnology Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 1 Aug 2026 — in the weakest quartile.
NNNN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Anbio Biotechnology on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (80): Sales and profits are climbing, and climbing faster than before.
Momentum (2): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Anbio Biotechnology — and when they’d sell — is the membership.
NNNN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NNNN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NNNN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Anbio Biotechnology (NNNN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 66.0×
- Price / sales
- 50.3×
- Price / book
- 14.4×
- EV / EBITDA
- 80.1×
Cheaper than 11% of US stocks
Cheaper than 6% of US stocks
Cheaper than 7% of US stocks
Cheaper than 3% of US stocks
- Revenue growth (YoY)
- 73.9%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 59.1%
- Net margin
- 74.1%
Higher than 91% of US stocks
Higher than 98% of US stocks
Higher than 98% of US stocks
- Return on equity
- 27.0%
- Return on assets
- 14.7%
- Dividend yield
- —
Higher than 86% of US stocks
Higher than 97% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
NNNN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NNNN appears on the weeks it earns a place.
Frequently asked questions about NNNN stock
How does Ticker Nerd's model rank NNNN?
As at 1 Aug 2026, Anbio Biotechnology ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (80 of 100).
What is the NNNN stock forecast for 2030?
No analyst covering Anbio Biotechnology publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NNNN are extrapolating price history, which says nothing about the business.
How has NNNN stock performed over the past year?
Anbio Biotechnology returned -75.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Anbio Biotechnology do?
Anbio Biotechnology Limited is a healthcare technology company specializing in the development and manufacturing of advanced in vitro diagnostic (IVD) products. Established in 2021, the company’s primary focus is to revolutionize diagnostics by delivering innovative solutions that support personalized and decentralized patient care.
About Anbio Biotechnology.
Anbio Biotechnology Limited is a healthcare technology company specializing in the development and manufacturing of advanced in vitro diagnostic (IVD) products. Established in 2021, the company’s primary focus is to revolutionize diagnostics by delivering innovative solutions that support personalized and decentralized patient care. Anbio Biotechnology offers a comprehensive portfolio of diagnostic products, including chemiluminescence immunoassays, lateral flow immunoassays, fluorescent immunoassays, polymerase chain reaction tests, and loop-mediated isothermal amplification. These platforms are designed for use in over-the-counter, point-of-care, and laboratory settings, facilitating rapid and accurate detection of a wide range of biomarkers related to infectious diseases, cancer, cardiovascular disorders, inflammation, drug abuse, endocrine and renal conditions, pharmacogenomics, and diabetes. By providing accessible and efficient diagnostic tools compatible with diverse sample types, such as blood, urine, saliva, and more, Anbio Biotechnology plays a vital role in enabling earlier intervention and improved health outcomes. The company serves healthcare providers and patients globally, responding to the rising demand for effective diagnostics and supporting the ongoing evolution toward precision medicine and decentralized healthcare delivery.
27 employees · Germany · https://www.anbiobiotechnology.com